Cost-effectiveness Analysis Between Two Anticoagulation Strategies for Atrial Fibrillation in the Postoperative Period of Coronary Artery Bypass Graft Surgery

NCT05300555 · clinicaltrials.gov ↗

PHASE4

Phase

UNKNOWN

Status

50

Enrollment

OTHER

Sponsor class

Conditions

Atrial Fibrillation New Onset

Interventions

DRUG: Rivaroxaban 20 MG Oral Tablet
DRUG: Warfarin

Sponsor

University of Sao Paulo General Hospital